Content is intended for people aged >18 years only
Allergan has a rich and promising pipeline of new therapeutics and innovative technologies in specialty areas including eye care, neurosciences, medical aesthetics, medical dermatology and urologics. We focus on novel therapies with the power to advance treatment paradigms and have numerous compounds in various stages of clinical development. More information about our clinical trials program can be found on: www.allerganclinicaltrials.com and www.clinicaltrials.gov.
Allergan has also provided regular updates to the European centralised database: www.clinicaltrialsregister.eu.
Adverse events should be reported. UK reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available at Google Play or Apple App stores.
Irish healthcare professionals (HCPs) are asked to report any suspected adverse reactions via HPRA Pharmacovigilance; website https://www.hpra.ie. Adverse events should also be reported to AbbVie on ProductSurveillance_EAME@allergan.com.
UK-AGNA-240104 Date of Preparation:- June 2024